Phase I study of afatinib + bevacizumab for advanced NSCLC with EGFR mutatio

Phase 1

• Conditions: on-small cell lung cancer

• Registration Number: JPRN-UMIN000016029
• Lead Sponsor: Juntendo University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-12-22
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1)Active double cancer 2)Interstitial pneumonitis on chest CT 3)Symptomatic brain metastases 4)Uncontrollable pleural effusion or pericardial effusion 5)Having hemoptysis 6)Having risk factor of bleeding 7)Gastrointestinal ulcer or past history of gastrointestinal perforation 8)Uncontrollable hyper tension 9)Active infectious disease 10)Receiving steroids or immunosuppressants 11)Receiving consecutive oxygen therapy 12)Inadequate period from open surgery 13)Planning open surgery 14)Pregnant or breastfeeding woman 15)History of severe allergy 16)Having other severe complications 17)Patients whose physicians considered as inappropriate for this clinical study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To conclude maximum tolerated dose and recommended phase II dose.